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Abstract
Background: Pharmacogenetic testing for drug-
metabolizing enzymes is not yet widely used in clini-
cal practice.
Methods: In an attempt to facilitate the application of
this procedure, we have compared two real-time PCR-
based methods, the TaqMan and the LightCycler
for the pharmacogenetic evaluation of CYP2C9*2/*3
polymorphisms.
Results and Conclusion: Both procedures are suitable
for pharmacogenetic studies. The TaqMan procedure
was less expensive in terms of cost per sample, but
the TaqMan apparatus is more expensive than the
LightCycler apparatus.
Keywords: cytochrome P450 (CYP450); pharmaco-
genetic testing; polymorphisms.
Pharmacogenetic testing for drug-metabolizing
enzymes is not widely used in clinical practice, prob-
ably because of a poor evidence base and a slow
translation of research results to the clinical setting
(1). A major drug-metabolizing enzyme is cytochrome
P450 2C9 (CYP2C9), which metabolizes over 100 cur-
rently used drugs (2, 3). Over 50 single nucleotide
polymorphisms (SNPs) have been identified in the
regulatory and coding regions of this gene (2). The
coding variants CYP2C9*2 (Arg144Cys) and CYP2C9*3
(Ile359Leu) reduce drug metabolism, which suggests
that drug dosage should be appropriately tailored in
patients carrying these variants (4). CYP2C9 geno-
types have been investigated mainly in relation to
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warfarin, an anticoagulant widely used to prevent
thromboembolic events in cardiovascular disease (5).
A simple, sensitive, rapid and accurate genotype
test would promote the use of pharmacogenetic test-
ing in laboratory practice. The most widely used
genotyping systems are: denaturing high-perform-
ance liquid chromatography (dHPLC); polymerase
chain reaction (PCR)-restriction fragment length poly-
morphisms; matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry; pyrosequenc-
ing; microarrays; and real-time PCR, each of which
has advantages and limitations (6).
We have compared the costs, analysis time, suc-
cess rate and versatility of two real-time PCR-based
methods, the TaqMan (Applied Biosystems, Foster
City, CA, USA) and LightCycler (Roche Diagnostics,
Mannheim, Germany) procedures, in the identifica-
tion of CYP2C9 polymorphisms. Using both instru-
ments, we genotyped 114 subjects (65 patients
undergoing therapy with warfarin for over 10 years
and 49 controls). All participants were recruited from
our University Hospital and gave informed consent to
the study. The study was approved by the Ethics
Committee of the School of Medicine of Naples Uni-
versity ‘‘Federico II’’ and was conducted in accor-
dance with the principles of the Helsinki II Declaration.
Briefly, a fasted blood sample was collected from
enrolled subjects in the morning after an overnight
fast. DNA was extracted with the Amersham Nu-
cleon BACC 2 Kit (Amersham Biosciences, Europe, Lit-
tle Chalfont, Buckinghamshire, England), and stored
at q48C until required. Anamnestic and clinical data
were collected from all patients.
The CYP2C9 *1 wild-type (wt), *2 and *3 polymor-
phic alleles were genotyped with the TaqMan proce-
dure (7, 8) and with the LightCycler Real Time PCR (9,
10), two procedures widely used to identify SNPs. The
pre-developed TaqMan assay reagent kit contains one
pair of PCR primers, one pair of fluorescent TaqMan
probes, and control templates. The PCR is set up in a
96-well plate with a 25-mL mix reaction and requires
50 ng of genomic DNA per assay. The PCR and the
subsequent allelic discrimination were carried out on
an ABI PRISM 7900 HT system (Applied Biosystems).
SDS 2.1 software (Applied Biosystems) was used to
analyze the fluorescent PCR products and to genotype
the samples. The LightCycler-CYP2C9 Mutation Detec-
tion Kit provides primers and hybridization probes for
sequence-specific detection, pre-mixed reagents, a
solution containing Fast Start Taq polymerase, and a
control template. The PCR is set up in glass capillaries
using 20 mL of mix reaction and 50 ng of genomic
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Table 1 Costs of analyzing CYP2C9*2/*3 polymorphisms using the LightCycler and TaqMan procedures.
Cost/test, 7
TaqMan LightCycler
Consumables (tips, well, 0.3661 1.2632 1.05
cover or capillaries) (96-test manual kit) (384-test automated kit) (32-test kit)
Reagent 6.25 1.25 13.06
Total cost 6.6 2.51 14.11
1Cost for 96 tests in manual; 2cost for 384 tests in automation using the Biomek Workstation.
Figure 1 Identification of CYP2C9 gene polymorphisms with the TaqMan (A) (PCR conditions: 508C for 2 min, 958C for 10 min,
followed by 35 cycles at 928C for 15 s and 608C for 1 min) and LightCycler (B) (PCR conditions: 958C for 10 min followed by
45 cycles at 958C for 10 s, 558C for 10 s, 728C for 10 s and 958C for 1 min, 408C for 1 min) systems.
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DNA, and is performed on the LightCycler system
(Roche Diagnostics); the three CYP2C9 alleles are
identified based on fluorescence measurements. The
costs and times required to isolate DNA and to set-up
the PCR mix were similar for both methods and are
therefore not included in the test comparison. In addi-
tion, the times required to determine CYP2C9*2/*3
genotypes after DNA isolation were comparable:
106 min with the TaqMan procedure (up to 48 sam-
ples) and 60 min with the LightCycler procedure (up
to 32 samples). The cost per sample, including re-
agents and consumables, was 76.61 for the TaqMan
set-up and 714.11 for the LightCycler system (see
Table 1). Moreover, the TaqMan procedure can be
automated using the 384-well apparatus and an auto-
mated workstation, thereby further decreasing the
cost/test. With the Biomek 2000 Workstation (Beck-
man Instruments, Fullerton, CA, USA) the test/cost
was 72.51. Both methods recommend a quality con-
trol procedure, consisting of one negative and two
positive (mutated and wt) homozygous controls
(TaqMan), or of one negative and one positive (het-
erozygous mutated) sample (LightCycler).
The advantages of the LightCycler were: (a) less risk
of contamination because a single glass capillary is
used; and (b) the cost per test is the same, irrespec-
tive of the number of samples (from 1 to 32), which
is useful when dealing with a low number of samples.
However, the glass capillaries are easily broken and
the cost per test is high. The advantages of the
TaqMan were: (a) a low cost per test, particularly for
high-throughput screening (from 96 to 384); and
(b) possible automation that further decreases the
costs. The TaqMan procedure has the disadvantage
that it is not suitable for a low number of assays and
the open-well plate entails a risk of contamination.
We tested the same sample 15 times to evaluate
reproducibility of the CYP2C9 assay, and the results
invariably overlapped with the two instruments. The
success rate, i.e., the number of runs successfully
completed with each instrument, was 97% (36/37
runs) with the TaqMan and 91% (29/32 runs) with the
LightCycler method. Failures were due to non-ampli-
fication of the positive control (TaqMan) and/or to the
quenching of 1/2 fluorochromes (LightCycler).
There was 100% concordance in the genotyping
results obtained with the two procedures. The
CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles were
present in 80.2%, 13.1% and 6.6%, respectively, of the
genotypes, which agrees with data reported for other
Italian samples (11, 12). Both kits produced unambig-
uous real-time sequence outputs (Figure 1A, B) and
were equally easy to use. The initial equipment costs
varied, depending on the model purchased, i.e.,
between 738,500 and 7110,000 for the TaqMan sys-
tem, and between 731,750 and 763,000 for the
LightCycler system.
In conclusion, the TaqMan and the LightCycler sys-
tems appear to be suitable for the pharmacogenetic
genotyping of CYP2C9 gene polymorphisms. The
TaqMan procedure was less expensive in terms of
cost per sample, but the TaqMan apparatus is more
expensive than the LightCycler apparatus.
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